Resources
118 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 11/30/2021 (updated 3/26/2024)
Peer providers are viable, evidence based, stand alone or additions to comprehensive teams that approach struggle interventions. Peer providers can be appropriate for any environment that have people with challenges ranging from substance use, gun violence, domestic violence to mental health experiences.
Learning Objectives:
What are the certifications that a peer provider can receive? You will walk away knowing various ways peers can show up in the workplace.
What additional training do peer providers need? Information on what trainings would be helpful for peers to be able to support others well will be provided.
How do we find, support and retain peer providers in the work place? Knowing where to recruit peers, how to keep the workplace well for peer will be knowledge you will leave with.
Presenter: Tanya Kraege
Posted 1/25/2022 (updated 3/26/2024)
RCORP-TA is pleased to provide technical assistance resources related to grantee business operations that we have prepared for grantees. RCORP-TA is providing these resources to assist grantees on aspects of their business operations that are continuously impacted and routinely challenged by factors associated with living and working in rural communities. Please see the below linked guidance documents and descriptions as they may be of interest to you.
Posted 2/9/2022 (updated 3/26/2024)
Summary of innovation abstracts that were presented at the National Academy of Medicine’s recent Stigma of Addiction Summit.
Posted 7/26/2023 (updated 3/26/2024)
This session covered key findings from the RCORP-Behavioral Health Care Support Year 1 Noncompeting Continuation Report.
Posted 7/28/2023 (updated 3/26/2024)
The toolkit Stimulant Safety: Getting Amped Up to Reduce Harms When Using Stimulants was developed through the CDC-funded National Harm Reduction Technical Assistance Center in collaboration with the NASTAD Drug User Health team and consultants. This resource provides education on the reasons people take stimulants, how to minimize harm, reduce stigma around stimulants, support peoples' positive experiences, the intersection of stimulant use and sexual safety, and much more.
Posted 8/18/2023 (updated 3/26/2024)
The National Institute on Drug Abuse (NIDA) Center for the Clinical Trials Network (CCTN) held an event where health care professionals and federal partners discussed xylazine-related testing, treatment, and wound care. As the White House has deemed fentanyl adulterated with xylazine an emerging threat, it is important to identify and adapt to the rapidly changing practices of patient care.
Posted 8/25/2023 (updated 3/26/2024)
The National Institute for Health Care Management (NIHCM) provided interactive graphic reports on the trends in overdose deaths using the latest data. The interactive infographic shows the effects combined drugs, such as fentanyl and xylazine, have on overdoses.
Posted 2/16/2022 (updated 3/26/2024)
Nearly 92,000 Americans died of drug overdoses in 2020, marking a 30% increase from the year before, a 75% increase over five years and by far the highest annual total on record, according to the Centers for Disease Control and Prevention (CDC). Preliminary figures suggest that the 2021 death toll from overdoses may be even higher.
While overdose death rates have increased in every major demographic group in recent years, no group has seen a bigger increase than Black men. As a result, Black men have overtaken White men and are now on par with American Indian or Alaska Native men as the demographic groups most likely to die from overdoses.
Posted 2/16/2022 (updated 3/26/2024)
In the United States, combined stimulant/opioid overdose mortality has risen dramatically over the last decade. These increases may particularly affect non-Hispanic Black and Hispanic populations. We used death certificate data from the US National Center for Health Statistics (2007–2019) to compare state-level trends in overdose mortality due to opioids in combination with 1) cocaine and 2) methamphetamine and other stimulants (MOS) across racial/ethnic groups (non-Hispanic White, non-Hispanic Black, Hispanic, and non-Hispanic Asian American/Pacific Islander).
Posted 3/3/2022 (updated 3/26/2024)
The US overdose crisis is driven by fentanyl, heroin, and prescription opioids. One evidence-based policy response has been to broaden naloxone distribution, but how much naloxone a community would need to reduce the incidence of fatal overdose is unclear. We aimed to estimate state-level US naloxone need in 2017 across three main naloxone access points (community-based programs, provider prescription, and pharmacy-initiated distribution) and by dominant opioid epidemic type (fentanyl, heroin, and prescription opioid).